Investing.com -- Thermo Fisher Scientific shares slid in premarket trading despite reporting first-quarter results that topped analyst expectations on both top and bottom line.

The company reported earnings per share (EPS) of $5.44, beating the consensus estimate of $5.25, while revenue rose 6% year-on-year to $11.01 billion, ahead of the $10.87 billion forecast.

Adjusted operating income climbed 6% from a year earlier to $2.40 billion, with adjusted operating margin coming in at 21.8%, roughly in line with the 21.9% recorded in the same period last year.

“We delivered a strong start to the year, reflecting excellent execution by our team, as we leveraged the PPI Business System to drive operational excellence and enable our customers’ success,” said Marc Casper, chairman and CEO of Thermo Fisher Scientific.

“Looking ahead, we are well-positioned to deliver a strong year. As the trusted partner to our customers, we are uniquely equipped to help them accelerate their innovation and enhance their productivity," he added.

The company said it would provide revised 2026 financial targets during the conference call at 8:30 a.m. Eastern Time.